In this two-part blog, we’ll first explore the technology roadmap to RBM we outlined and discussed, and next week we’ll bring you some key themes addressing practical considerations in adopting an RBM approach in your next clinical study.
"With the new day comes new strength and new thoughts." — Eleanor Roosevelt
What does GDPR mean for you?
The stakes for delays in clinical research are high.
A dialogue with Glen de Vries, president of Medidata, and Ken Banta, founder of the Vanguard Group for Leadership.